CHIL Achieves Record COVID-19 Test Production Capacity with Second Factory
In May 2021, CHIL rapidly commissioned its second manufacturing facility in just one month to meet the surging demand for…
CHIL Achieves 100% IgG Specificity in Global SARS-CoV-2 Antibody Study
On February 8, 2021, a research article titled “Comparison of the Clinical Performance and Usefulness of Five SARS-CoV-2 Antibody Tests”…
CHIL Expanded R&D Team to Drive Advanced Diagnostic Innovation
In January 2021, CHIL’s R&D department expanded from 12 to 43 experts, forming a highly diverse and multidisciplinary team. The…
CHIL Joins the Fight Against COVID-19 in the U.S. with First Export
On 27 November 2020, CHIL completed its first export to the United States, becoming one of the manufacturers actively supporting…
Navigating Challenges: CHIL at MEDICA
Amidst the global pandemic, CHIL took part in MEDICA Messe Düsseldorf from November 16 to 19, 2020, reinforcing its commitment…
From Antibody Testing to Rapid Antigen Innovation: CHIL Among the First Global Developers
In 2020, at the onset of the COVID-19 pandemic, diagnostic availability was largely limited to antibody (serology) tests, primarily used…
CHIL-Backed COVID-19 Test Donation Broadcast on Peruvian TV
During the COVID-19 pandemic, CHIL provided urgent support to its long-standing partners in Peru by supplying diagnostic tests. On 25…
CHIL Products Recognized for Excellence in Belarus
On 18 June 2020, following CHIL’s export to Belarus, the Belarus Ministry of Health formally acknowledged the quality and performance…
CHIL Delivers First COVID-19 Antibody Tests Amid Global Pandemic
In May 2020, at the height of the COVID-19 pandemic, CHIL achieved a major milestone by delivering its first COVID-19…
Adapting and Engaging: CHIL at Medlab Middle East
Despite the emerging global challenges of 2020, CHIL participated in Medlab Middle East in Dubai, from February 3 to 6,…